Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

NLM Logo

Immunotherapy, Adoptive MeSH Descriptor Data 2025


MeSH Heading
Immunotherapy, Adoptive
Tree Number(s)
E02.095.465.425.400.330.050.400
E05.478.550.520.050.400
Unique ID
D016219
RDF Unique Identifier
http://id.nlm.nih.gov/mesh/D016219
Annotation
for CAR T-Cell Therapy, coordinate with RECEPTORS, CHIMERIC ANTIGEN
Scope Note
Form of adoptive transfer where cells with antitumor activity are transferred to the tumor-bearing host in order to mediate tumor regression. The lymphoid cells commonly used are lymphokine-activated killer (LAK) cells and tumor-infiltrating lymphocytes (TIL). This is usually considered a form of passive immunotherapy. (From DeVita, et al., Cancer, 1993, pp.305-7, 314)
Entry Version
IMMUNOTHER ADOPTIVE
Entry Term(s)
Adoptive Cellular Immunotherapy
Adoptive Immunotherapy
CAR T-Cell Therapy
Cellular Immunotherapy, Adoptive
Chimeric Antigen Receptor Therapy
Immunotherapy, Adoptive Cellular
NLM Classification #
QW 940
Previous Indexing
Immunization, Passive (1983-1990)
See Also
Receptors, Chimeric Antigen
History Note
1991
Date Established
1991/01/01
Date of Entry
1990/06/06
Revision Date
2018/07/02
Immunotherapy, Adoptive Preferred
Chimeric Antigen Receptor Therapy Narrower
page delivered in 0.125s